221 related articles for article (PubMed ID: 37949414)
1. The spatiotemporal journey of nanomedicines in solid tumors on their therapeutic efficacy.
Qin M; Xia H; Xu W; Chen B; Wang Y
Adv Drug Deliv Rev; 2023 Dec; 203():115137. PubMed ID: 37949414
[TBL] [Abstract][Full Text] [Related]
2. Current Approaches for Improving Intratumoral Accumulation and Distribution of Nanomedicines.
Durymanov MO; Rosenkranz AA; Sobolev AS
Theranostics; 2015; 5(9):1007-20. PubMed ID: 26155316
[TBL] [Abstract][Full Text] [Related]
3. Mathematical modeling of the heterogeneous distributions of nanomedicines in solid tumors.
He H; Liu C; Liu Y; Liu X; Wu Y; Fan J; Zhao L; Cao Y
Eur J Pharm Biopharm; 2019 Sep; 142():153-164. PubMed ID: 31226367
[TBL] [Abstract][Full Text] [Related]
4. Modulating tumor mechanics with nanomedicine for cancer therapy.
Zhao Q; Chen J; Zhang Z; Xiao C; Zeng H; Xu C; Yang X; Li Z
Biomater Sci; 2023 Jun; 11(13):4471-4489. PubMed ID: 37221958
[TBL] [Abstract][Full Text] [Related]
5. Effect of biophysical properties of tumor extracellular matrix on intratumoral fate of nanoparticles: Implications on the design of nanomedicine.
Tian Y; Cheng T; Sun F; Zhou Y; Yuan C; Guo Z; Wang Z
Adv Colloid Interface Sci; 2024 Apr; 326():103124. PubMed ID: 38461766
[TBL] [Abstract][Full Text] [Related]
6. Tumor-Targeted Nanomedicine for Immunotherapy.
Cabral H; Kinoh H; Kataoka K
Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
[TBL] [Abstract][Full Text] [Related]
7. Nanomedicines for advanced cancer treatments: Transitioning towards responsive systems.
van Elk M; Murphy BP; Eufrásio-da-Silva T; O'Reilly DP; Vermonden T; Hennink WE; Duffy GP; Ruiz-Hernández E
Int J Pharm; 2016 Dec; 515(1-2):132-164. PubMed ID: 27725268
[TBL] [Abstract][Full Text] [Related]
8. Challenging the fundamental conjectures in nanoparticle drug delivery for chemotherapy treatment of solid cancers.
Yang J; Wang X; Wang B; Park K; Wooley K; Zhang S
Adv Drug Deliv Rev; 2022 Nov; 190():114525. PubMed ID: 36100142
[TBL] [Abstract][Full Text] [Related]
9. Strategies of engineering nanomedicines for tumor retention.
Qian X; Xu X; Wu Y; Wang J; Li J; Chen S; Wen J; Li Y; Zhang Z
J Control Release; 2022 Jun; 346():193-211. PubMed ID: 35447297
[TBL] [Abstract][Full Text] [Related]
10. Tumor-targeted nanomedicines for cancer theranostics.
Arranja AG; Pathak V; Lammers T; Shi Y
Pharmacol Res; 2017 Jan; 115():87-95. PubMed ID: 27865762
[TBL] [Abstract][Full Text] [Related]
11. Unraveling the role of Intralipid in suppressing off-target delivery and augmenting the therapeutic effects of anticancer nanomedicines.
Islam R; Gao S; Islam W; Šubr V; Zhou JR; Yokomizo K; Etrych T; Maeda H; Fang J
Acta Biomater; 2021 May; 126():372-383. PubMed ID: 33774199
[TBL] [Abstract][Full Text] [Related]
12. Enhancing Tumor Penetration of Nanomedicines.
Sun Q; Ojha T; Kiessling F; Lammers T; Shi Y
Biomacromolecules; 2017 May; 18(5):1449-1459. PubMed ID: 28328191
[TBL] [Abstract][Full Text] [Related]
13. Current understandings and clinical translation of nanomedicines for breast cancer therapy.
Jiang Y; Jiang Z; Wang M; Ma L
Adv Drug Deliv Rev; 2022 Jan; 180():114034. PubMed ID: 34736986
[TBL] [Abstract][Full Text] [Related]
14. Combining Nanomedicine and Immunotherapy.
Shi Y; Lammers T
Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
[TBL] [Abstract][Full Text] [Related]
15. Rational Design of Cancer Nanomedicine: Nanoproperty Integration and Synchronization.
Sun Q; Zhou Z; Qiu N; Shen Y
Adv Mater; 2017 Apr; 29(14):. PubMed ID: 28234430
[TBL] [Abstract][Full Text] [Related]
16. Design considerations for nanotherapeutics in oncology.
Stylianopoulos T; Jain RK
Nanomedicine; 2015 Nov; 11(8):1893-907. PubMed ID: 26282377
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic efficacy of nanomedicines for prostate cancer: An update.
Lakshmanan VK
Investig Clin Urol; 2016 Jan; 57(1):21-9. PubMed ID: 26966723
[TBL] [Abstract][Full Text] [Related]
18. Recent Advances in Targeted Tumor Chemotherapy Based on Smart Nanomedicines.
Qin SY; Zhang AQ; Zhang XZ
Small; 2018 Nov; 14(45):e1802417. PubMed ID: 30247806
[TBL] [Abstract][Full Text] [Related]
19. Tumor Abnormality-Oriented Nanomedicine Design.
Zhou Q; Xiang J; Qiu N; Wang Y; Piao Y; Shao S; Tang J; Zhou Z; Shen Y
Chem Rev; 2023 Sep; 123(18):10920-10989. PubMed ID: 37713432
[TBL] [Abstract][Full Text] [Related]
20. Tumor extravasation and infiltration as barriers of nanomedicine for high efficacy: The current status and transcytosis strategy.
Zhou Q; Dong C; Fan W; Jiang H; Xiang J; Qiu N; Piao Y; Xie T; Luo Y; Li Z; Liu F; Shen Y
Biomaterials; 2020 May; 240():119902. PubMed ID: 32105817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
